MTOR inhibitors and the anti-diabetic biguanide metformin: New insights into the molecular management of breast cancer resistance to the HER2 tyrosine kinase inhibitor lapatinib (Tykerb®)

Clinical and Translational Oncology

Volumn 11, Issue 7, 2009, Pages 455-459

  Vázquez Martín, Alejandro ^a,b   Oliveras Ferraros, Cristina ^a,b   Del Barco, Sonia ^a,b   Martín Castillo, Begona ^a,b   Menéndez, Javier A ^a,b  

^a CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^b HOSPITAL JOSEP TRUETA   (Spain)

Author keywords

HER2; Lapatinib; Metformin; MTOR; Rapamycin; Tyrosine kinase inhibitors; Vreast cancer

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HER2 PROTEIN, HUMAN; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

BIOLOGICAL MODEL; BREAST TUMOR; DRUG ANTAGONISM; DRUG RESISTANCE; FEMALE; HUMAN; METABOLISM; REVIEW; TUMOR CELL LINE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; METFORMIN; MODELS, BIOLOGICAL; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; QUINAZOLINES; RECEPTOR, ERBB-2;

EID: 70450021431     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-009-0384-0     Document Type: Article

References (27)

1. Nahta R, Yu D, Hung MC et al (2006) Mechanisms of disease: Understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 3:269-280
2. Chen FL, Xia W, Spector NL (2008) Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors. Clin Cancer Res 14:6730-6734
3. Nagata Y, Lan KH, Zhou X et al (2004) PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6:117-127
4. Xia W, Husain I, Liu L et al (2007) Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers. Cancer Res 67:1170-1175
5. Xia W, Bacus S, Hegde P et al (2006) A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. Proc Natl Acad Sci U S A 103:7795-7800
6. Eichhorn PJA, Gili M, Scaltriti M et al (2008) Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res 68:9221-9230
7. Maira SM, Stauffer F, Brueggen J et al (2008) Identification and characterization of NVPBEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 7:1851-1863
8. Serra V, Markman B, Scaltriti M et al (2008) NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 68:8022-8030
9. Vazquez-Martin A, Oliveras-Ferraros C, Colomer R et al (2008) Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerb) in human breast carcinoma cells. Ann Oncol 19:1097-1109
10. Zakikhani M, Dowling R, Fantus IG et al (2006) Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 66:10269-10273
11. Dowling RJ, Zakikhani M, Fantus IG et al (2007) Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 67:10804-10812
12. Shell SA, Lyass L, Trusk PB et al (2008) Activation of AMPK is necessary for killing cancer cells and sparing cardiac cells. Cell Cycle 7:1769-1775
13. Anisimov VN, Berstein LM, Egormin PA et al (2005) Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Exp Gerontol 40:685-693
14. Anisimov VN, Egormin PA, Bershtein LM et al (2005) Metformin decelerates aging and development of mammary tumors in HER-2/neu transgenic mice. Bull Exp Biol Med 139:721-723
15. Zhang L, He H, Balschi JA (2007) Metformin and phenformin activate AMP-activated protein kinase in the heart by increasing cytosolic AMP concentration. Am J Physiol Heart Circ Physiol 293:H457-H466
16. Jin Q, Feng L, Behrens C et al (2007) Implication of AMP-activated protein kinase and Akt-regulated survivin in lung cancer chemopreventive activities of deguelin. Cancer Res 67:11630-11639
17. Vazquez-Martin A, Oliveras-Ferraros C, del Barco S et al (2009) The antidiabetic drug metformin: A pharmaceutical AMPK activator to overcome breast cancer resistance to HER2 inhibitors while decreasing risk of cardiomyopathy. Ann Oncol 20:592-595
18. Xia W, Bisi J, Strum J et al (2006) Regulation of survivin by ErbB2 signaling: Therapeutic implications for ErbB2-overexpressing breast cancers. Cancer Res 66:1640-1647
19. Hede K (2008) Doctors seek to prevent breast cancer recurrence by lowering insulin levels. J Natl Cancer Inst 100:530-532
20. Goodwin PJ, Pritchard KI, Ennis M et al (2008) Insulin-lowering effects of metformin in women with early breast cancer. Clin Breast Cancer 8:501-505
21. Berstein LM (2009) Metformin, insulin, breast cancer and more⋯ Future Oncol 5:309-312
22. Jiralerspong S, Giordano SH, Meric-Bernstam F et al (2008) The effects of metformin on pathological complete response (pCR) rates in diabetic breast cancer (BC) receiving neoadjuvant systemic therapy (NST). J Clin Oncol 26[Suppl 15]:13s [ASCO Abstract 528]
23. Cazzaniga M, Bonanni B, Guerrieri-Gonzaga A, Decensi A (2009) Is it time to test metformin in breast cancer clinical trials? Cancer Epidemiol Biomarkers Prev 18:701-705
24. Oliveras-Ferraros C, Vazquez-Martin A, Menendez JA (2009) Genome-wide inhibitory impact of the AMPK activator metformin on [kinesins, tubulins, histones, auroras and polo-like kinases] M-phase cell cycle genes in human breast cancer cells. Cell Cycle 8:1633-1636
25. Liu B, Fan Z, Edgerton SM et al (2009) Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle 8 [Epub ahead of print]
26. Alimova IN, Liu B, Fan Z et al (2009) Metformin inhibits breast cancer cells growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle 8:909-915
27. Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA (2009) The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells. Cell Cycle 8:88-96